The short answer: Often yes — if you meet BMI criteria and your plan includes anti-obesity medications. Most commercial plans require prior authorization. Medicare Part D generally does not cover Wegovy for weight loss alone.
Wegovy (semaglutide 2.4mg) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for chronic weight management. It is a higher-dose formulation of the same active ingredient in Ozempic (used for type 2 diabetes). In clinical trials, Wegovy produced an average weight loss of 15–17% of body weight over 68 weeks. The FDA also approved Wegovy to reduce the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease.
Coverage varies significantly by payer. Large commercial employers are the most likely to cover Wegovy — a 2024 KFF employer survey found that about 44% of large employers cover GLP-1 drugs for weight loss. Most require prior authorization.
Most insurers require prior authorization for Wegovy. Typical requirements include:
Denials are common on first submission. About 40% of appeals succeed when properly documented. Your appeal should include: a letter of medical necessity from your provider detailing your BMI, comorbidities, and prior weight loss attempts; peer-reviewed evidence supporting Wegovy's efficacy; and a statement that denial creates a health risk.
Ask your prescriber to specifically document cardiovascular risk factors. Wegovy's FDA approval for CV risk reduction gives insurers less grounds to deny the medication outright.
If your plan won't cover Wegovy, compounded semaglutide is a legal cash-pay alternative from $145/mo.
Get a personalized coverage estimate in 60 seconds based on your insurer, diagnosis, and state.
Check My Coverage →Coverage data is based on publicly available formulary information and reported patient outcomes as of 2026. This is not medical or insurance advice. Always verify coverage directly with your insurer.